Acid reflux medication safety
Pro Research Analysisby 
Searched over 200M research papers
Safety of Acid Reflux Medications: PPIs, P-CABs, and Antacids
Proton Pump Inhibitors (PPIs) Safety Concerns
Proton pump inhibitors (PPIs) are widely used as the first-line treatment for gastroesophageal reflux disease (GERD) and have a generally acceptable safety profile for short-term use. However, concerns have been raised about their long-term safety. Studies show that prolonged PPI use is associated with an increased risk of infections (such as gastrointestinal and respiratory infections), nutritional deficiencies, and possibly bone health issues. The evidence for increased cancer risk is less convincing, but regular reassessment of the need for ongoing PPI therapy is recommended to minimize unnecessary exposure Ali2009Safe2016. In children and infants, the use of PPIs and H2 antagonists has been linked to a higher risk of serious infections, including necrotizing enterocolitis, sepsis, pneumonia, and gastrointestinal infections, and their effectiveness in this population is questionable Chung2013Safe2016.
Potassium-Competitive Acid Blockers (P-CABs) Safety Profile
Potassium-competitive acid blockers (P-CABs), such as vonoprazan, are newer acid-suppressive medications that have shown similar or even superior efficacy compared to PPIs for GERD, including in patients who do not respond to PPIs. Clinical trials and meta-analyses indicate that the safety of P-CABs in short-term use is comparable to that of PPIs, with low rates of adverse events and serious adverse events reported. However, more data are needed to fully understand their long-term safety, especially considering factors like age, ethnicity, drug interactions, and genetic differences. Ongoing pharmacovigilance is recommended to monitor for potential risks over time Tietto2024Lesmana2023Zhou2024+2 MORE.
Antacids: Safety and Use in Self-Management
Antacids remain a mainstay for the self-management of heartburn and acid reflux symptoms due to their rapid action, over-the-counter availability, and favorable safety profile. They are generally recommended for adults and children over 12 years old and are considered safe for use during pregnancy. Antacids are effective for mild, occasional symptoms but are not suitable for long-term management of chronic GERD .
Comparative Safety in Endoscopy-Negative Reflux Disease
Comparative studies of PPIs, P-CABs, histamine-2 receptor antagonists, and alginates in patients with endoscopy-negative reflux disease suggest that all these medications have similar safety profiles, with no significant differences in the incidence of adverse events among them .
Conclusion
Acid reflux medications, including PPIs, P-CABs, and antacids, are generally safe when used appropriately. PPIs and P-CABs have similar short-term safety profiles, but long-term PPI use may increase the risk of infections and nutritional deficiencies, especially in vulnerable populations like children and infants. P-CABs appear well-tolerated in the short term, but more research is needed on their long-term effects. Antacids are safe for occasional use and self-management. Regular review of ongoing acid suppression therapy is important to minimize unnecessary risks.
Sources and full results
Most relevant research papers on this topic